Equine influenza antigen-based particle vaccine protects mice against homologous and heterosubtypic viral challenges.

ABSTRACT: Influenza virus is a common source of respiratory illness and poses a major public health burden globally. Significant efforts have been dedicated towards developing and deploying effective vaccines. However, since being licensed in 1945, influenza vaccines have made limited progress and still suffer from several limitations, including suboptimal efficacy against variants. In this work, we report on two influenza A polyanhydride particle- and pentablock copolymer-based vaccine formulations intended for intranasal or subcutaneous administration. These nanovaccines are based on a newly discovered equine influenza A H3N8 hemagglutinin antigen (A/equine/1/KY/91), A/HK/1/68 nucleoprotein antigen, and a small molecule adjuvant. When these nanovaccines were administered to naïve mice, both formul

SUBMITTER: Siddoway AC 

PROVIDER: S-EPMC12798653 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature